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• Coronary and Oontm~ila Effects of lntrecomnnry 
Bmdylrdnin and Their Modulation by AGE Inhibitor 
in Normal Conec lo~ Dogs 
ROmi HouIH, Jinbo Su, Fabdce Barbe, ROmi Choussat, Bertrand Crozatier, 
Luc Wd~nger. INSERM U400, Facult~ de M~[~ecine, CrOtett, France 
inhibition of bra4yldnin (BK) degradation may contribute to the hamodynamio 
effects of angiotansin converting enzyme (ACE) inhibitors. In this study, we 
examined in normal conscious dogs, the coronary and contractile ffects of 
intracerona~ (ic) BK and their medul~on by ACE inhibitor, To avoid neu- 
rorsflex activations low doces of SKwere used (0.1,1, 3,10 nanogr~ 
lc bolus). The effects of i,c. BK were also examined in the presence of the 
ACE inhibitor enalapdlat (E) given intracoronarily (0,75 rag) and orally (20 
rag). Seven mongrel dogs were chronically instromented with left vantdcoter 
(LV) mlcromenometer, amt~ catheter, corormry flow probe, circumgex coro- 
nary catheter and ptescelactlo crystals for the measurement of LV posterior 
regional ventriceiar function. In absence of systemic hemedynarelo changes, 
low doses of BK increased ose-dependently coronary blood flow (CBF ve- 
!getty: 30 :t: 5, 42 ± 7, 45 ~ 8, 48 :E 7 cm/s, respectively, frore 19 =1:3 cites). 
The increase in CBF induced by BK was associated with an increase in end- 
diastolic regional wall thickness (BK 10 ag/kg: from 11.9:1:1.1 to 12.4:1:1.1 
mm, p < 0.01) without change in LV regional well thickening. Intmceronary 
enalapd~at extended sign'dicantty he duration of the rtsa in CBF induced 
by BK (10 ng/kg: from 42 :~ 5 to I16 ± 15 sac, p < 0,01) without change 
in peak effect. After enatapdlat a further increase in the end-diastolic w~| 
thickness was observed (E + BK 10 ng/kg: 13.4 -t- 1.2 mm, p < 0.05) with 
no change in regional con~.~l~. Simi'ar findings were observed one hour 
after oral administration of enalapdl. Thus, in normal conscious dogs, SK 
increases coronary blood flow and end<liaatofic wall thickness with no effect 
on myocardial contractility. Infraceronary or oral administration ofenatapdlat 
does not change the contractile response to BK but prolongs the coronary 
vasnditator effect of bmdykinin. 
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• Hsemodynamlo and Endocrine Effects of ANP and 
BNP in Pulmonary Heart Disease 
Rot~ert t.Cargill, 8finn J. Upworth. Oepartmenf of Clinica~ Pharmacology, 
Unive~ity of Dundee, Scotland, UK 
We have aludled the effects of atdal natdurstio peptide (ANP) and b-type 
nalrluratic peptido (BNP) in eight patients with pulmonary heart disease 
secondary to hypoxaemio lung disease. E~ pat!ant was studied twice in 
cross-over fashion. After resting to reach bassline hasmedynamiss, ubjects 
were given a 20 minute placebo infusion, followed by either ANP or BNP 
(3 pmol/kg/min than 10 pmol/kg/min for 20 rains each). Responses were 
measored at baseline, after placebo infusion, and following low then high 
dose ANP or BNP. 
Baseline conditions were similar and placebo infusion had no aignificant 
effects on either study day. Low dose ANP and BNP significantly reduced 
m- :m pulmonary artery pressure (MPAP) from baseline by 3.7 :t: 1.1 mmHg 
and 3.0 ± 1.1 mmHg respectively High dose ANP and BNP further educed 
MPAP from baseline by 7.1 ~: 1.1 mmHg and 7.1 at: 1.6 mmHg respectively. 
ANP and BNP had no confounding systemic haemedynareio effects and 
did not woman artedal oxygenation, Plasma aldostarona was significantly 
suppressed by ANP ( -  156 :t: 48 pmol/1 after fuw dose, - 275 :E 57 pmci/1 
after high dose) and by BNP ( -  92 =E 36 pmol/I after low dose, - 159 -v 55 
pmol/1 after high dose), 
ANP and BNP soused dose-related pulmonary vesedilatatlon and had 
favoursbla neurehormonal effects by suppressing aldoaterona, without were. 
an(ng oxygen saturation or affecting systemic haemodynamlce, These ac- 
tions might herefore be exploited as a novel therapeutic strategy in patients 
with pulmonary heart disease. 
Long Term Effects of Ctclatanine on Secondary 
Pulmonary Hypertension 
Alain SasdJlan, Fran(;cls Philip-Jolt, Franck Paganegi, Alaln Amaud, 
Samuel Levy. University of Morse!lie, Cardiology Dpt, CHU Noro~ 13915 
Marseille, France 
Clcletenine ((3), an antihypartensive furopyrld[na dodvative drug was shown 
to enhance the production of endogenous prostacyciln. The goal of the 
present work was to evaluate the possible effecla of C on pulmonary artery 
hypertension (PAH) secondary tO chronic obatm~ve lung dJsaase (COLD). 
In a doul~e blind placebo controlled study, we evakmted the long term effeots 
of C (SO mg per ca (laity) on hamndynamios and btood gases of 33 patients 
(pts) sutfedng from PAH secondary to COLD. Pie receiving C (11) and those 
(12) who had a placebo (P) were catheterized betom traatment (TO) then 3 
months iT3) and 12 months later (T12). 
Results (mean ± SEM): 
CIcletan[ne Placebo C/P 
TO 13 T12 TO T3 3"12 
CI 2.8=1:0.2 3330,2* 3,230.2 2.830,2 2.830.1 ~230,1 ce 
MPAP 27 =t: 2 23 =l: 2" 22-*.2* 303)-2 29:~3 2932 <0.05 
PWP 114-1 1031 9:E1 12±1 1331 11=1:1 ns 
TPR 454:b28 36P.:~31" 8814-43" 507348 474±47 48934 <0,05 
Pa02 6432 5833* 5933* 60~=3 6133 5e.~.4 n= 
Gk cardiac index (Umlrdn~-), MPAP: mean puimenaly artery pressure, PWP: po|mecery 
wage pmuum (mmHg), TPR: total pulmonary esistance (dynes.era.We). PC02 (rnmHg). 
*d~er,~nca (p < O.0S) between TO and 1'3 er/T12. 
A signiticant decrease in MPAP and TPR was observed in group C and 
between C and P attar 3 months of treatment and persisted after 12. Pa02 
decreased slightly in group C but the difference with group P was not sig- 
nificant, These results suggest that tong term treatment with tow dose C 
can induce an effective pulmonary rased!!st!on in pts with PAH secondary to 
COLD, This vasodtlation is associated with a alight venous admixture. 
~ T h e  Pulmonary Circulation Is on Important Site for 
Both Clearance and Prnduction of  Endotheiln-1 in 
Humans 
Jecelyn Oupuis, Gilbert Gosaelin, Duncan J. Stewart, Peter Cemacek. 
Montreal Heart Institute and Montreal Genera! Hospital, Montreal, C, anade 
Animal studies suggest a meier rate of the pulmona~ circulation in the 
clearance of circulating endotheiln-1 (ET-1). The contribution of the human 
pulmonary circulation to plasma ET-1 has however never been quantified, 
To precisely quantify and discern botwean ET-1 clearance and produ~on, 
we studied patients during elective coronary anglography by combining the 
multiple Indicator dilution technique with simultaneous measurement of im- 
munoreastive ET-1 levels in companion aortic and pulmonary artery blood 
samples. A be!us containing trace dosaa of [125]-I-ET.1 and Evens blue dye 
was injected into the pulmonary artery and timed samples from the aorta 
were collected to construct a dlfution cunm. Ni pet!ante had normal isft yen- 
trice!or election haction (61 :E "P/,; M -I- SO) and baseline puimonmy and 
systemic hemodynamlss (mean pulmonary artery pmasure: 16 ± 4 mmHg). 
Mean cumulative tracer ET-1 extraction was 47 :~ "P/o during a s|nl;~e put- 
monary transit ime, The ET-1 extracted oes not return to the circulation and 
can be characterized by a sequestration rate constant: K=~ = 0,048 -~ 0.019 
s -1. There was however no significant difference between immunoraactive 
ET-1 !eveis from the pulmonaw artery (0.61 ~ 0,29 pg/ml) end aorta (0.67 :E 
0.32 pg/ml): the normal ung consequently produces an amount of ET-1 that 
is quantitatively alrollar to the quantity that has been extracted. Conclusion: 
The human tung is an important site for beth clearance and production of 
ET-1. There is a normal physiologic "balance" of ET-1 across the pulmonary 
circulating explaining the absence of difference in attedovenoua ET-I levels 
despite a 47 :E 7% clearance. Reduced pulmona,'y clearance or increased 
production of this paptlde may contribute to the increase in circulating levels 
found in various cardiovascular conditions. 
~ Digox!n Partly Restores the Abnormal Circadian 
Pattern of Autonomic Control During Daytime but 
Not D. u_rin.g Nighttime In Patients With Congsetlve 
r lel l l l  PSllUre 
Jan Breuwer, Dirk J. van Valdhuisen, Ado J. Man in 't Void, Peter 
HJM, Ounsefman, Jaap Hasksma, K.L Lie for the DIMT Study Group. 
Groningen, The Netherlands 
Recently, we den~onctmted that treatment w~h dtgoxin enhances cardiac 
vega! tOne in patina-Its with mtld to moderate congestive heart failure (CHF). TO 
evaluate if this effect Is present hroughout the day, we studied the clmadlan 
pattern of h~.art rate variability (HRV) parameters In 22 CHF patients (age 60 
:E 1 years (mean :E SEM), ejection fraction 0.30.4- 0.0I) and in 18 healthy 
controls (age 55 4-1 years), The CHF patisnts were treated with digoxln 0.25 
mg once daily for 3 months, Analysis of HRV was performed using 24 Hr 
Holler recordings and included time end frequency domain parameters. At 
baseline, all HRV pommeters ahowed a reduced circadian pattero In the CHF 
patients as competed to the haatthy controls. After treatment with digoxlr~ 
pNNSO increased significantly from 2,9 at: 0.7% to 4.9 ~ 1 .~ (p < 0.05) 
dudng daytime hours in the CHF petiants. Highz ,fi~:luency poW~z(0.15-O 40 
Hz) also showed an increase from 117 ± 22 ms to 175 ~- 34 ms (p < 0.01) 
dudng daytime bourn, Low frequency power (0.04-0.15 Hz) showed a small 
